Alcon (ALC) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.84
- Estimate
- $0.76
- Surprise
- +11.2%
- Score at report (before → after)
- 5.3 → 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Alcon (ALC) beat the $0.76 estimate with adjusted EPS of $0.84 — a large 11.2% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Hold at 5.2/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALC Hold at 5.3/10.
3 of the last 4 quarters beat the estimate; this quarter's +11.2% surprise compares with a +4.2% four-quarter average. Next scheduled report: 2026-11-10.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Thin upside margin: 5.7%
- Below 200-MA, MA slope -2.8%/30d (confirmed downtrend)
- Momentum score 4.2/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $69.83
- Price target
- $73.79
- Stop
- $67.03
- Upside to target
- +5.7%
- Reward-to-risk
- 0.5:1
The stock trades at 52.9× trailing but 17.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 75 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
ALC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $33.76B
- P/E (fwd)
- 17.7
- P/E (ttm)
- 52.9
- 52-week range
- $61.84–$87.64
- Off 52-week high
- 20.3%
- RSI (14)
- 75
- Volume vs avg
- 0.66×
- Score today
- 5.3/10